BeOne Medicines, BeOne Care Foundation, and The Max Foundation extend collaboration to broaden access to BRUKINSA for chronic lymphocytic leukemia patients in low- and middle-income countries

BeOne Medicines Ltd., a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable organization, and The Max Foundation, a leading global health nonprofit, announced they have extended their partnership through 2028 to broaden access to BRUKINSA® (zanubrutinib) for treating chronic lymphocytic leukemia in low- and middle-income countries. The program is expected to support roughly 1,000 patients in total by the time it concludes.

Building on a collaboration that began in 2023, the renewed agreement reflects the organizations’ shared commitment to expanding access to advanced cancer treatments in communities that are often underserved. So far, the partnership has provided access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, surpassing the program’s original goal by roughly 150 patients and helping establish access to innovative cancer treatment for patients who previously had few or no options available to them.

The collaboration pairs The Max Foundation’s experience running oncology access programs with donated supplies of BRUKINSA from BeOne Medicines, along with a $1 million grant from the BeOne Care Foundation to support patient care, engagement with physicians, and operational infrastructure over the coming two years.

Pat Garcia-Gonzalez, co-founder and CEO of The Max Foundation, said the organization is pleased to extend its collaboration with BeOne and the BeOne Care Foundation and to further broaden access to advanced treatment for people living with CLL in low- and middle-income countries. She said working closely with partner physicians in Armenia, Ethiopia, and Nepal has allowed the program to help hundreds of patients access treatment, enabling many to keep supporting their families, spend time with loved ones, and remain active in their communities. She welcomed the shared commitment from BeOne Medicines and the BeOne Care Foundation to extend CLL treatment access to more countries, patients, and families, bringing dignity and hope to those who need it.

John V. Oyler, co-founder, chairman, and CEO of BeOne Medicines, said the company’s goal from the outset has been to make sure that where someone lives does not determine whether they can access high-quality cancer care. He said renewing the partnership with The Max Foundation reflects both the impact already achieved together and the companies’ commitment to reaching many more patients who might otherwise have limited treatment options.

Christine Riley Miller, president of the BeOne Care Foundation, said the foundation was created to help remove barriers to accessible cancer care in underserved communities. She said investing in partners such as The Max Foundation helps expand access to transformative medicines and strengthens the support systems patients need to achieve the best possible outcomes.

---

---

Related Topics and Keywords

beone medicines, brukinsa, chronic lymphocytic leukemia